Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intra-abdominal infection and new quinolones].

C A Gnocchi1

  • 1Departamento de Medicina, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Argentina.

Medicina
|August 7, 1999
PubMed
Summary

Intra-abdominal infection, often severe, carries a high mortality. Effective antibiotic treatment for secondary peritonitis targets specific bacteria like Escherichia coli and Bacteroides fragilis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Septic thrombophlebitis of the portal vein associated with reversible portal hypertension].

Medicina·2002
Same author

[Digoxin: continuous or discontinuous treatment?].

Medicina·1998
Same author

[Renal vascular lesion and microangiopathic hemolytic anemia in systemic lupus erythematosus].

Medicina·1997
Same author

[Preoperative clinical evaluation].

Medicina·1997

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Surgical Infections

Context:

  • Intra-abdominal infection involves infectious processes within the peritoneal cavity, potentially leading to systemic dysfunction and high mortality rates.
  • Secondary peritonitis arises from gastrointestinal tract integrity loss, causing polymicrobial contamination, primarily by Gram-negative bacilli.
  • Prognosis hinges on host immunity versus contamination severity, with sepsis triggered by microbial products and inflammatory mediators.

Purpose:

  • To outline the definition, causes, and prognosis of intra-abdominal infections, focusing on secondary peritonitis.
  • To detail appropriate antibiotic strategies for secondary peritonitis based on infection severity and acquisition source (community vs. hospital-acquired).
  • To differentiate secondary peritonitis from tertiary peritonitis, highlighting the latter's systemic inflammatory response and multiorganic failure.

Summary:

  • Antibiotic therapy for secondary peritonitis must target Escherichia coli and Bacteroides fragilis, with empirical choices guided by infection localization, severity, and origin.
  • Community-acquired peritonitis may be treated with combinations like metronidazole-ceftriaxone or ampicillin-sulbactam, while severe hospital-acquired cases warrant imipenem or piperacillin-tazobactam.
  • Emerging quinolones show promise, but further clinical trials are necessary to establish their role in managing these complex infections.

Impact:

  • Provides critical guidance for clinicians in selecting optimal empirical antibiotic regimens for secondary peritonitis.
  • Highlights the importance of considering patient-specific factors and infection characteristics for improved treatment outcomes.
  • Differentiates between treatable secondary peritonitis and the often intractable tertiary peritonitis, informing patient management and prognosis.

Related Experiment Videos